JP2010531140A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010531140A5 JP2010531140A5 JP2010512689A JP2010512689A JP2010531140A5 JP 2010531140 A5 JP2010531140 A5 JP 2010531140A5 JP 2010512689 A JP2010512689 A JP 2010512689A JP 2010512689 A JP2010512689 A JP 2010512689A JP 2010531140 A5 JP2010531140 A5 JP 2010531140A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- antibody
- acid sequence
- igf
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001413 amino acids Chemical group 0.000 claims 20
- 108020004414 DNA Proteins 0.000 claims 15
- 102000053602 DNA Human genes 0.000 claims 12
- 210000004027 cell Anatomy 0.000 claims 9
- 238000000034 method Methods 0.000 claims 8
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 claims 7
- 102000048143 Insulin-Like Growth Factor II Human genes 0.000 claims 7
- 239000013604 expression vector Substances 0.000 claims 7
- 230000001404 mediated effect Effects 0.000 claims 6
- 102000038455 IGF Type 1 Receptor Human genes 0.000 claims 4
- 108010031794 IGF Type 1 Receptor Proteins 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 102000003746 Insulin Receptor Human genes 0.000 claims 3
- 108010001127 Insulin Receptor Proteins 0.000 claims 3
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims 3
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 210000004962 mammalian cell Anatomy 0.000 claims 3
- 230000011664 signaling Effects 0.000 claims 3
- 239000013598 vector Substances 0.000 claims 3
- 102000004877 Insulin Human genes 0.000 claims 2
- 108090001061 Insulin Proteins 0.000 claims 2
- 206010039491 Sarcoma Diseases 0.000 claims 2
- 230000002424 anti-apoptotic effect Effects 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 229940125396 insulin Drugs 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 201000003076 Angiosarcoma Diseases 0.000 claims 1
- 206010004593 Bile duct cancer Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 239000012623 DNA damaging agent Substances 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 208000006168 Ewing Sarcoma Diseases 0.000 claims 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims 1
- 208000001258 Hemangiosarcoma Diseases 0.000 claims 1
- 101000976075 Homo sapiens Insulin Proteins 0.000 claims 1
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 claims 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010027406 Mesothelioma Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 claims 1
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 1
- 208000026900 bile duct neoplasm Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 208000011654 childhood malignant neoplasm Diseases 0.000 claims 1
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 1
- 210000003238 esophagus Anatomy 0.000 claims 1
- 201000010175 gallbladder cancer Diseases 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 210000000777 hematopoietic system Anatomy 0.000 claims 1
- 102000044162 human IGF1 Human genes 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 230000002297 mitogenic effect Effects 0.000 claims 1
- 108010088102 mouse insulin-like growth factor-1 Proteins 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 108010077161 rat insulin-like growth factor-1 Proteins 0.000 claims 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims 1
- 230000019491 signal transduction Effects 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 238000001890 transfection Methods 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07110587 | 2007-06-19 | ||
| PCT/EP2008/057789 WO2008155387A2 (en) | 2007-06-19 | 2008-06-19 | Anti-igf antibodies that bind to igf-1 and igf-2 but not to insulin |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010531140A JP2010531140A (ja) | 2010-09-24 |
| JP2010531140A5 true JP2010531140A5 (enExample) | 2011-08-11 |
Family
ID=39154657
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010512689A Pending JP2010531140A (ja) | 2007-06-19 | 2008-06-19 | 抗ｉｇｆ抗体 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US8580254B2 (enExample) |
| EP (1) | EP2220119B1 (enExample) |
| JP (1) | JP2010531140A (enExample) |
| AR (1) | AR067046A1 (enExample) |
| CA (1) | CA2689521A1 (enExample) |
| CL (1) | CL2008001814A1 (enExample) |
| PE (1) | PE20090368A1 (enExample) |
| TW (1) | TW200909446A (enExample) |
| UY (1) | UY31160A1 (enExample) |
| WO (1) | WO2008155387A2 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1797881B1 (en) | 2004-09-17 | 2009-04-15 | Eisai R&D Management Co., Ltd. | Medicinal composition with improved stability and reduced gelation properties |
| WO2007015578A1 (ja) * | 2005-08-02 | 2007-02-08 | Eisai R & D Management Co., Ltd. | 血管新生阻害物質の効果を検定する方法 |
| ES2556173T3 (es) | 2006-05-18 | 2016-01-13 | Eisai R&D Management Co., Ltd. | Agente antitumoral para un cáncer de tiroides |
| PE20090368A1 (es) | 2007-06-19 | 2009-04-28 | Boehringer Ingelheim Int | Anticuerpos anti-igf |
| CN101848895B (zh) * | 2007-11-09 | 2013-10-23 | 卫材R&D管理有限公司 | 血管新生抑制物质和抗肿瘤性铂络合物的组合使用 |
| HRP20160190T1 (hr) * | 2008-12-12 | 2016-03-25 | Boehringer Ingelheim Int | Protutijela anti-igf |
| EP2400985A2 (en) * | 2009-02-25 | 2012-01-04 | OSI Pharmaceuticals, LLC | Combination of an either an anti-igf-1r antibody or an igf binding protein and a small molecule igf-1r kinase inhibitor |
| TW201102068A (en) * | 2009-06-02 | 2011-01-16 | Novartis Ag | Treatment of ophthalmologic disorders mediated by alpha-carbonic anhydrase isoforms |
| AU2010303383B2 (en) | 2009-10-07 | 2014-07-31 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human domain antibodies against components of the human insulin-like growth factor (IGF) system |
| AU2014256364B2 (en) * | 2009-10-07 | 2016-07-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human domain antibodies against components of the human insulin-like growth factor (IGF) system |
| PL2719708T3 (pl) * | 2009-11-13 | 2018-04-30 | Daiichi Sankyo Europe Gmbh | Materiał i sposoby leczenia lub zapobiegania chorobom związanym z HER-3 |
| EP2382976A1 (en) | 2010-04-30 | 2011-11-02 | Hiroshima University | Use of pdgf-r inhibitors for the treatment of lymph node metastasis of gastric cancer |
| CA2802644C (en) * | 2010-06-25 | 2017-02-21 | Eisai R & D Management Co., Ltd. | Antitumor agent using compounds having kinase inhibitory effect in combination |
| RU2580609C2 (ru) | 2011-04-18 | 2016-04-10 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Противоопухолевое терапевтическое средство |
| EP3444363B1 (en) | 2011-06-03 | 2020-11-25 | Eisai R&D Management Co., Ltd. | Biomarkers for prediciting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds |
| AU2013364953A1 (en) | 2012-12-21 | 2015-04-30 | Eisai R&D Management Co., Ltd. | Amorphous form of quinoline derivative, and method for producing same |
| US20140255413A1 (en) | 2013-03-07 | 2014-09-11 | Boehringer Ingelheim International Gmbh | Combination therapy for neoplasia treatment |
| WO2014185540A1 (en) | 2013-05-14 | 2014-11-20 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds |
| US20140378401A1 (en) * | 2013-06-21 | 2014-12-25 | Gnt, Llc | Ophthalmic Lipophilic and Hydrophilic Drug Delivery Vehicle Formulations |
| EP3096792B1 (en) * | 2014-01-24 | 2019-09-25 | Boehringer Ingelheim International GmbH | Cancer treatment using an insulin-like growth factor (igf) receptor antagonist in combination with exemestane and everolimus |
| US9737535B2 (en) * | 2014-04-16 | 2017-08-22 | Signal Pharmaceuticals, Llc | Methods for treating cancer using TOR kinase inhibitor combination therapy comprising administering substituted pyrazino[2,3-b]pyrazines |
| KR102329681B1 (ko) | 2014-08-28 | 2021-11-23 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 고순도의 퀴놀린 유도체 및 이를 제조하는 방법 |
| KR20250024102A (ko) | 2015-02-25 | 2025-02-18 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 퀴놀린 유도체의 고미 억제 방법 |
| AU2015384801B2 (en) | 2015-03-04 | 2022-01-06 | Eisai R&D Management Co., Ltd. | Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer |
| ES2886107T3 (es) | 2015-06-16 | 2021-12-16 | Prism Biolab Co Ltd | Antineoplásico |
| SG11201801083UA (en) | 2015-08-20 | 2018-03-28 | Eisai R&D Man Co Ltd | Tumor therapeutic agent |
| CN115844877B (zh) * | 2017-01-10 | 2024-07-23 | 浙江嘉驰医药开发有限公司 | 拉索昔芬调节膜结合雌激素信号的应用及治疗癌症的方法 |
| US12303505B2 (en) | 2017-02-08 | 2025-05-20 | Eisai R&D Management Co., Ltd. | Tumor-treating pharmaceutical composition |
| US20200197384A1 (en) | 2017-05-16 | 2020-06-25 | Eisai R&D Management Co., Ltd. | Treatment of hepatocellular carcinoma |
Family Cites Families (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) * | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4342566A (en) * | 1980-02-22 | 1982-08-03 | Scripps Clinic & Research Foundation | Solid phase anti-C3 assay for detection of immune complexes |
| EP0561137B1 (en) | 1983-04-25 | 2002-07-03 | Chiron Corporation | Hybrid DNA Synthesis of Mature Insulin-like Growth Factors |
| WO1985000831A1 (en) | 1983-08-10 | 1985-02-28 | Amgen | Microbial expression of insulin-like growth factor |
| AU1232188A (en) | 1987-05-29 | 1988-12-01 | Mallinckrodt, Inc. | Novel pair of monoclonal antibodies to insulin-like growth factor i permits immunometric assay for igf-i |
| DE68908175T2 (de) | 1988-05-27 | 1994-03-03 | Centocor Inc | Gefriergetrocknete formulierung für antikörperprodukte. |
| JPH03501487A (ja) | 1988-06-30 | 1991-04-04 | シティ・オブ・ホープ | インシュリン模倣物およびインシュリンリセプター結合部位ペプチド |
| CA2058041A1 (en) | 1990-06-27 | 1991-12-28 | Katsuichi Sakano | Anti-igf-ii monoclonal antibody |
| ES2108460T3 (es) | 1993-06-03 | 1997-12-16 | Therapeutic Antibodies Inc | Fragmentos de anticuerpos en terapeutica. |
| WO1995025794A1 (en) | 1994-03-23 | 1995-09-28 | Japan Clinical Laboratories | Anti-igf-i monoclonal antibody |
| US6685940B2 (en) * | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
| US5916771A (en) * | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| US6991790B1 (en) * | 1997-06-13 | 2006-01-31 | Genentech, Inc. | Antibody formulation |
| GB9722131D0 (en) * | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
| DE69834828T2 (de) * | 1997-11-27 | 2007-01-04 | Commonwealth Scientific And Industrial Research Organisation | Verfahren zur konstruktion von agonisten und antagonisten des igf-rezeptors (1-462) |
| AU763954B2 (en) * | 1999-04-28 | 2003-08-07 | Board Of Regents, The University Of Texas System | Compositions and methods for cancer treatment by selectively inhibiting VEGF |
| SV2007000775A (es) * | 2001-01-05 | 2007-03-15 | Pfizer | Anticuerpos contra el receptor del factor de crecimiento similar a insulina |
| RU2420537C2 (ru) | 2001-01-17 | 2011-06-10 | Трабьон Фармасьютикалз Инк. | Слитые белки связывающий домен-иммуноглобулин |
| WO2004058821A2 (en) | 2002-12-27 | 2004-07-15 | Domantis Limited | Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand |
| EP1399484B1 (en) | 2001-06-28 | 2010-08-11 | Domantis Limited | Dual-specific ligand and its use |
| US20050214857A1 (en) | 2001-12-11 | 2005-09-29 | Algonomics N.V. | Method for displaying loops from immunoglobulin domains in different contexts |
| ATE357460T1 (de) | 2002-01-18 | 2007-04-15 | Pf Medicament | Antikörper gegen igf-ir und ihre verwendungen |
| US7438911B2 (en) * | 2002-04-30 | 2008-10-21 | Kyowa Hakko Kogyo Co., Ltd. | Antibody against human insulin-like growth factor |
| JP2003310275A (ja) | 2002-04-30 | 2003-11-05 | Kyowa Hakko Kogyo Co Ltd | ヒトインスリン様成長因子に対する遺伝子組換え抗体 |
| KR101086533B1 (ko) | 2002-05-24 | 2011-11-23 | 쉐링 코포레이션 | 중화 사람 항-ｉｇｆｒ 항체, 이를 제조하는 방법 및 이를 포함하는 조성물 |
| US8034904B2 (en) | 2002-06-14 | 2011-10-11 | Immunogen Inc. | Anti-IGF-I receptor antibody |
| US7538195B2 (en) | 2002-06-14 | 2009-05-26 | Immunogen Inc. | Anti-IGF-I receptor antibody |
| DK1517921T3 (da) | 2002-06-28 | 2006-10-09 | Domantis Ltd | Immunglobulin-enkeltvariable antigen-bindende domæner og dobbeltspecifikke konstruktioner deraf |
| JP2006517581A (ja) | 2003-02-13 | 2006-07-27 | ファイザー・プロダクツ・インク | 抗インスリン様増殖因子ｉ受容体抗体の使用 |
| JP2007528201A (ja) | 2003-03-14 | 2007-10-11 | ファルマシア・コーポレーション | 癌治療のためのｉｇｆ−ｉ受容体に対する抗体 |
| ES2527871T3 (es) | 2003-05-01 | 2015-02-02 | Imclone Llc | Anticuerpos completamente humanos dirigidos contra el receptor del factor de crecimiento 1 similar a la insulina humana |
| US7579157B2 (en) | 2003-07-10 | 2009-08-25 | Hoffmann-La Roche Inc. | Antibody selection method against IGF-IR |
| WO2005018671A1 (ja) | 2003-08-21 | 2005-03-03 | Kyowa Hakko Kogyo Co., Ltd. | 癌転移阻害剤 |
| ATE492562T1 (de) | 2003-09-24 | 2011-01-15 | Kyowa Hakko Kirin Co Ltd | Rekombinanter antikörper gegen humanen insulin- like growth factor |
| JPWO2005027970A1 (ja) | 2003-09-24 | 2007-11-15 | 協和醗酵工業株式会社 | 癌治療用医薬 |
| WO2005058967A2 (en) | 2003-12-16 | 2005-06-30 | Pierre Fabre Medicament | Novel anti-insulin/igf-i hybrid receptor or anti-insulin/igf-i hybrid receptor and igf-ir antibodies and uses thereof |
| JP2008506681A (ja) | 2004-07-16 | 2008-03-06 | ファイザー・プロダクツ・インク | 抗ｉｇｆ−１ｒ抗体を用いる非血液性の悪性腫瘍の併用療法 |
| MY146381A (en) | 2004-12-22 | 2012-08-15 | Amgen Inc | Compositions and methods relating relating to anti-igf-1 receptor antibodies |
| EP2799451A1 (en) * | 2005-05-24 | 2014-11-05 | MorphoSys AG | Generation and profiling of fully human HuCAL GOLD®-derived therapeutic antibodies specific for human CD38 |
| FR2888850B1 (fr) | 2005-07-22 | 2013-01-11 | Pf Medicament | Nouveaux anticorps anti-igf-ir et leurs applications |
| CA2625681C (en) | 2005-10-12 | 2016-08-02 | Morphosys Ag | Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human cd38 |
| JP5302007B2 (ja) | 2005-12-13 | 2013-10-02 | アストラゼネカ アクチボラグ | インスリン様増殖因子に特異的な結合タンパク質およびその使用 |
| EP1999149A4 (en) | 2006-03-28 | 2010-01-20 | Biogen Idec Inc | ANTI-IGF-1R ANTIBODIES AND USES THEREOF |
| EP2010567A2 (en) | 2006-04-07 | 2009-01-07 | The Government of the United States of America as Represented by The Department of Health and Human Services | Antibody compositions and methods for treatment of neoplastic disease |
| US20080014203A1 (en) | 2006-04-11 | 2008-01-17 | Silke Hansen | Antibodies against insulin-like growth factor I receptor and uses thereof |
| KR20090023423A (ko) | 2006-06-02 | 2009-03-04 | 화이자 프로덕츠 인코포레이티드 | 순환 종양 세포 분석 |
| EP2405270B1 (en) | 2006-06-30 | 2013-07-17 | Merck Sharp & Dohme Corp. | IGFBP2-Biomarker |
| US7749966B2 (en) * | 2006-12-21 | 2010-07-06 | Boston Biomedical Research Institute | Immunological modulation of insulin-like growth factor 1 for cancer prevention/treatment and prolonging longevity |
| AR064464A1 (es) | 2006-12-22 | 2009-04-01 | Genentech Inc | Anticuerpos anti - receptor del factor de crecimiento insulinico |
| GB0702888D0 (en) | 2007-02-14 | 2007-03-28 | Glaxo Group Ltd | Novel Antibodies |
| AU2008223541B2 (en) | 2007-03-02 | 2012-04-05 | Amgen Inc. | Methods and compositions for treating tumor diseases |
| WO2008115470A2 (en) | 2007-03-16 | 2008-09-25 | East Carolina University | Hox-gene expression as a biomarker for igf-1r therapeutics |
| MX2009010179A (es) | 2007-03-22 | 2010-03-15 | Imclone Llc | Formulaciones estables de anticuerpo. |
| WO2008144345A2 (en) | 2007-05-17 | 2008-11-27 | Bristol-Myers Squibb Company | Biomarkers and methods for determining sensitivity to insulin growth factor-1 receptor modulators |
| US8178091B2 (en) * | 2007-05-21 | 2012-05-15 | University Of Washington | Compositions and methods for the treatment of respiratory disorders |
| WO2008152422A2 (en) | 2007-06-12 | 2008-12-18 | Astrazeneca Ab | Binding proteins specific for insulin-like growth factors and uses thereof-909 |
| PE20090368A1 (es) | 2007-06-19 | 2009-04-28 | Boehringer Ingelheim Int | Anticuerpos anti-igf |
| WO2009006336A1 (en) | 2007-06-28 | 2009-01-08 | Sylgen Laboratories, Inc. | Compositions and methods for inhibiting angiogenesis and tumorigenesis |
| US20110014117A1 (en) | 2007-06-28 | 2011-01-20 | Schering Corporation | Anti-igf1r |
| WO2009017679A2 (en) | 2007-07-31 | 2009-02-05 | Merck & Co., Inc. | Igf-1r specific antibodies useful in the detection and diagnosis of cellular proliferative disorders |
| EP2190879A1 (en) | 2007-08-01 | 2010-06-02 | Glaxo Group Limited | Novel antibodies |
| US8426557B2 (en) | 2007-08-03 | 2013-04-23 | Affibody Ab | IGF-1R binding polypeptides and their use |
| JP5777340B2 (ja) | 2007-08-06 | 2015-09-09 | オリオン ゲノミクス エルエルシー | Ｉｇｆ２遺伝子の対立遺伝子特異的な発現を判定するための一塩基多型ならびに新規および公知の多型の組み合わせ |
| CA2697922A1 (en) | 2007-08-28 | 2009-03-12 | Biogen Idec Ma Inc. | Compositions that bind multiple epitopes of igf-1r |
| CN101842117A (zh) | 2007-08-28 | 2010-09-22 | 比奥根艾迪克Ma公司 | 抗igf-1r抗体及其用途 |
| US20090186951A1 (en) | 2007-09-19 | 2009-07-23 | Brody Jerome S | Identification of novel pathways for drug development for lung disease |
| CA2694154A1 (en) | 2007-10-03 | 2009-04-09 | Osi Pharmaceuticals, Inc. | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
| JP2011501660A (ja) | 2007-10-03 | 2011-01-13 | オーエスアイ・ファーマスーティカルズ・インコーポレーテッド | インスリン様成長因子−１受容体キナーゼ阻害剤に対する抗癌反応を予測する生物学的マーカー |
| EP2247757A2 (en) | 2007-12-18 | 2010-11-10 | Schering Corporation | Biomarkers for sensitivity to anti-igf1r therapy |
| US20090258365A1 (en) | 2008-03-25 | 2009-10-15 | Terstappen Leon W M M | METHOD FOR DETECTING IGF1R/Chr 15 in CIRCULATING TUMOR CELLS USING FISH |
| CN102065895A (zh) | 2008-04-11 | 2011-05-18 | 比奥根艾迪克Ma公司 | 抗-igf-1r抗体和其它化合物的治疗联合 |
| MX2010012064A (es) | 2008-05-05 | 2010-12-06 | Schering Corp | Uso secuencial de agentes quimioterapeuticos citotoxicos para el tratamiento de cancer. |
| AU2009244091B2 (en) | 2008-05-09 | 2014-11-27 | Commonwealth Scientific And Industrial Research Organisation | IGF-II/GF-IIE binding proteins |
| EP2297208A4 (en) | 2008-06-03 | 2012-07-11 | Abbott Lab | DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND ITS USES |
| NZ591651A (en) | 2008-09-26 | 2012-12-21 | Merck Sharp & Dohme | High titer antibody production and culture media comprising glucose, soy or wheat hydrolsyate, amino acids, and other chemical compounds |
| CN102164960A (zh) | 2008-09-26 | 2011-08-24 | 罗氏格黎卡特股份公司 | 双特异性抗-egfr/抗-igf-1r抗体 |
| JP2012505900A (ja) | 2008-10-14 | 2012-03-08 | ダイアクス コーポレーション | 全身性強皮症に伴う肺線維症の治療および予防のためのｉｇｆ−ｉｉ／ｉｇｆ−ｉｉｅ結合タンパク質の使用 |
| US8163509B2 (en) | 2008-10-20 | 2012-04-24 | The Regents Of The University Of Colorado, A Body Corporate | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
| AU2009312731B2 (en) | 2008-11-10 | 2012-12-20 | Novartis Ag | Antibodies to modified human IGF-1/E peptides |
| WO2010062896A1 (en) | 2008-11-28 | 2010-06-03 | Abbott Laboratories | Stable antibody compositions and methods for stabilizing same |
| HRP20160190T1 (hr) * | 2008-12-12 | 2016-03-25 | Boehringer Ingelheim Int | Protutijela anti-igf |
| WO2010069858A1 (en) | 2008-12-19 | 2010-06-24 | F. Hoffmann-La Roche Ag | Pharmaceutical composition |
| JP2012513477A (ja) | 2008-12-23 | 2012-06-14 | ソーク インスティチュート フォー バイオロジカル スタディーズ | 神経変性疾患の治療方法 |
-
2008
- 2008-06-17 PE PE2008001030A patent/PE20090368A1/es not_active Application Discontinuation
- 2008-06-18 TW TW097122727A patent/TW200909446A/zh unknown
- 2008-06-18 UY UY31160A patent/UY31160A1/es not_active Application Discontinuation
- 2008-06-18 CL CL2008001814A patent/CL2008001814A1/es unknown
- 2008-06-18 AR ARP080102595A patent/AR067046A1/es unknown
- 2008-06-19 EP EP08761223.0A patent/EP2220119B1/en not_active Not-in-force
- 2008-06-19 US US12/665,373 patent/US8580254B2/en active Active
- 2008-06-19 CA CA002689521A patent/CA2689521A1/en not_active Abandoned
- 2008-06-19 JP JP2010512689A patent/JP2010531140A/ja active Pending
- 2008-06-19 WO PCT/EP2008/057789 patent/WO2008155387A2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010531140A5 (enExample) | ||
| TWI806895B (zh) | 抗體-藥物結合物之新穎製造方法 | |
| ME02377B (me) | Anti-igf antitijela | |
| JP2009505676A5 (enExample) | ||
| JP2020501531A5 (enExample) | ||
| JP2020502271A5 (enExample) | ||
| JP2009526010A5 (enExample) | ||
| JP2013502913A5 (enExample) | ||
| JP2017186337A5 (enExample) | ||
| CA2798390A1 (en) | Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies | |
| TW201909926A (zh) | Ｂ７ｈ３抗體－藥物偶聯物及其醫藥用途 | |
| JP2009541492A5 (enExample) | ||
| RU2014101669A (ru) | Агенты, связывающие белки r-спондины (rspo), и способы их применения | |
| Hong et al. | Chemoenzymatic Synthesis of a Rhamnose‐Functionalized Bispecific Nanobody as a Bispecific Antibody Mimic for Cancer Immunotherapy | |
| JP2009525764A5 (enExample) | ||
| JP2019536430A5 (enExample) | ||
| WO2022187539A1 (en) | Methods of treating cancer using multi-specific binding proteins that bind nkg2d, cd16 and a tumor-associated antigen | |
| JP2018520650A5 (enExample) | ||
| HRP20150256T1 (hr) | Djelatna sredstva za vezanje notch1-receptora i postupci njihove uporabe | |
| JP2010535713A5 (enExample) | ||
| CA2618681A1 (en) | Identification and engineering of antibodies with variant fc regions and methods of using same | |
| RU2014109039A (ru) | Биспецифические антигенсвязывающие молекулы | |
| JP2012509259A5 (enExample) | ||
| WO2015146132A1 (ja) | 抗ｃｄ９８抗体－薬物コンジュゲート | |
| TW202108181A (zh) | 抗trop2抗體及其生產方法、及抗trop2抗體-藥物結合物 |